---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-031684"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2024-10-22T23:59:59+00:00"
generated_at: "2026-05-30T11:40:18.396187+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Monopar presents positive uPAR radiopharma dosimetry data at EANM 2024

## Summary
- MNPR-101-Lu shows favorable organ safety at high Lu-177 doses using human Zr-89 dosimetry data.
- Presentation accepted as 'Top-Rated Oral Presentation' at EANM 2024 in Hamburg, Germany.
- Preclinical and clinical data show favorable biodistribution, tumor uptake, and low off-target binding.
- MNPR-101-Lu ongoing Phase 1a trial (NCT06617169); MNPR-101-Zr imaging trial (NCT06337084).

## SEC filing metadata
- accession: 0001437749-24-031684
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2024-10-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000143774924031684/0001437749-24-031684-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000143774924031684/mnpr20241021c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-031684
- JSON: https://secwatch.observer/filing/0001437749-24-031684.json
- Plain text: https://secwatch.observer/filing/0001437749-24-031684.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.